Actos, Pioglitazone News

An NDA for alogliptin monotherapy was submitted on September 29, 2008 and is now under evaluation by regulatory authorities.

The U.S. Food and Drug Administration postponed the approval of alogliptin, a drug to treat type 2 diabetes.

Takeda Pharmaceuticals has received a request from the U.S. Food & Drug Administration for additional safety studies on SYR-322, also known by the general name alogliptin, used for diabetes treatment.

In a blow to the diabetes treatment franchise of a Deerfield drug maker, the U.S. Food and Drug Administration has asked Takeda Pharmaceuticals North America Inc.

Takeda Pharmaceutical Co. a s new diabetes drug faces a likely delay by U.S. regulators this week, leaving the company without a contender to replace sales of its star diabetes pill Actos when its patent expires in 18 months.

Treatment with the diabetes drug Actos, known technically as pioglitazone, seems to reduce brain shrinkage and may have other beneficial effects in people with multiple sclerosis , researchers report.

June 16, 2009 - Translational Genomics Research Institute scientists have identified five genetic biomarkers that could help lead to improved treatments, with fewer side-effects, for patients with diabetes.

A class of oral diabetes drugs, commonly nicknamed "glitazones." Unlike the traditional oral drugs called sulfonylureas , which lower blood glucose levels by making the pancreas secrete more insulin, the thiazolidinediones work by helping the body's tissues to use insulin more effectively and by suppressing glucose production by the liver.

Proliferator-activated receptor gamma agonists appear to protect against and halt progression of both hypertension-related and age-related glomerulosclerosis, reports Agnes B. Fogo, professor of pathology, medicine, and pediatrics, Vanderbilt University, Nashville, TN .

InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose thiazolidinedione therapy but with less hematocrit reduction and weight gain.

New investigational data presented at the American Diabetes Association 69th Annual Scientific Sessions showed that initial combination therapy with 'Januvia' and pioglitazone* substantially improved blood sugar control.

The results from the phase II SYNCHRONY study are published in an article Online First and in a future edition of The Lancet .

VeroScience, in collaboration with S2 Therapeutics, announced the presentation of clinical and preclinical data at the American Diabetes Association 69th Scientific Sessions on Cycloset, a novel treatment for patients with Type 2 diabetes.

Earnings Estimates Revisions They're the most powerful force driving stock prices, and the key to the Zacks Rank's market-beating track record.

NIH Finds Patients With Heart Disease Fare Equally Well Without Stents and Drugs Such as Avandia, Actos By KEITH J. WINSTEIN Aggressive use of expensive diabetes drugs and medical devices called stents did no better than cheaper treatments at preventing deaths, heart attacks or strokes in a large study of diabetics with heart disease.

Research presented at the American Diabetes Association's 69th Scientific Sessions points to increased risk for people with diabetes associated with two widely used drug classes; while another study shed new light on a different class of drugs that faced increased scrutiny from the US Food and Drug Administration .

Initial type 2 diabetes treatment with a combination of sitagliptin and pioglitazone produced more robust hemoglobin A1c lowering than either agent alone, and sitagliptin as add-on therapy to insulin with or without metformin also showed significantly enhanced HbA1c reduction compared to insulin alone.

The high-profile experimental once-weekly injectable diabetes drug from Amylin Pharmaceuticals Inc and Eli Lilly and Co proved superior to the widely used medicines Actos and Januvia in a clinical trial, according to data presented on Saturday.

Merck & Co.a s diabetes pill Januvia, as part of a combination therapy, improved blood-sugar levels more than taking either insulin or Takeda Pharmaceutical Co.a s Actos alone, two company studies said.

In two new investigational studies evaluating the efficacy and tolerability of Merck & Co., Inc.